Lung Cancer Interception Research Team - Stand Up To Cancer

Research Teams

Research  >  Research Portfolio  >  Research Teams  >  Lung Cancer Interception Research Team

SU2C–LUNGevity–American Lung Association Lung Cancer Interception Research Team:
Blood-Based Early Interception of Lung Cancer

Grant Term: December 2017–February 2019

The Team’s fundamental premise was that improving early detection of invasive lung cancers is a solvable technological problem that can be immediately linked to a definitive clinical treatment. The Team built a test, called the Lung Cancer Interception Assay, as a composite blood-based biomarker assay that could be used in conjunction with standard imaging. 

Supported by:

ABOUT THIS TEAM’S RESEARCH

The SU2C-LUNGevity-American Lung Association Lung Cancer Interception Research Team worked to develop a Lung Cancer Interception Assay (LCIA), based on blood-based assays that examine circulating tumor cells and circulating tumor DNA, that could be used in conjunction with low-dose CT scans to provide early detection of lung cancer.

MEET THE TEAM

The top scientists and researchers on the SU2C–LUNGevity–ALA Lung Cancer Interception Research Team come from a variety of backgrounds and disciplines, which leads them to great insights upon collaboration. Learn more about the SU2C–LUNGevity–ALA Lung Cancer Interception Research Team.

Team Members

Lecia V. Sequist, MD
Massachusetts General Hospital Cancer Center
Leader

Maximilian Diehn, MD, PhD
Stanford University School of Medicine
Co-leader

PuiYee (Elaina) Chan, PhD
Massachusetts General Hospital
Project Manager

Chris Draft
Chris Draft Family Foundation
Advocate

“It’s extremely frustrating that we’re not technically able to find lung cancer earlier in the majority of patients. We need to change the paradigm that we use to identify patients so that they are found early enough to offer them curative treatment. If we really want to save more lives from lung cancer, we have to exponentially improve our diagnostics.”

Lecia V. Sequist, MD
Massachusetts General Hospital Cancer Center

TEAM PROGRESS UPDATES

The SU2C-LUNGevity-American Lung Association Lung Cancer Interception Research Team worked to develop a Lung Cancer Interception Assay (LCIA), based on blood-based assays that examine circulating tumor cells and circulating tumor DNA, that could be used in conjunction with low-dose CT scans to provide early detection of lung cancer.

TEAM PROGRESS UPDATES

PUBLICATIONS

To date, this team has not published its research.

CLINICAL TRIALS REFERRALS

Cancer clinical trials allow researchers to study innovative and potentially life-saving new treatments. The goal is to find treatments that are better than what’s currently available, in fact the therapies offered to today’s cancer patients were almost all studied and made possible by people participating in clinical trials. But many cancer clinical trials don’t get completed because not enough people participate.

At StandUpToCancer.org/ClinicalTrials, you’ll find information and answers to common questions about clinical trials. Learn more and talk to your doctor to see if a clinical trial may be the best choice for you.

LEARN MORE

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.